Portage Biotech (NASDAQ:PRTG) Stock Price Down 1.6%

Shares of Portage Biotech Inc. (NASDAQ:PRTGGet Rating) dropped 1.6% during trading on Friday . The stock traded as low as $4.91 and last traded at $4.92. Approximately 113,958 shares changed hands during trading, an increase of 173% from the average daily volume of 41,754 shares. The stock had previously closed at $5.00.

Wall Street Analysts Forecast Growth

PRTG has been the subject of several research reports. Cantor Fitzgerald lowered their price objective on shares of Portage Biotech from $26.00 to $18.00 in a research report on Wednesday, November 30th. Oppenheimer reduced their target price on shares of Portage Biotech from $26.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 30th. Finally, HC Wainwright reduced their target price on shares of Portage Biotech from $22.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, December 1st.

Portage Biotech Stock Down 1.6 %

The firm has a market cap of $83.37 million, a PE ratio of -4.92 and a beta of 1.34. The company’s 50 day moving average price is $5.65 and its two-hundred day moving average price is $7.05.

Institutional Investors Weigh In On Portage Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. purchased a new stake in shares of Portage Biotech in the second quarter valued at $79,000. Beacon Investment Advisory Services Inc. purchased a new position in Portage Biotech in the 2nd quarter worth about $80,000. Millennium Management LLC purchased a new position in Portage Biotech in the 2nd quarter worth about $92,000. Dimensional Fund Advisors LP purchased a new position in Portage Biotech in the 3rd quarter worth about $107,000. Finally, Citadel Advisors LLC purchased a new position in Portage Biotech in the 2nd quarter worth about $137,000. Hedge funds and other institutional investors own 0.67% of the company’s stock.

About Portage Biotech

(Get Rating)

Portage Biotech Inc, together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT230-6 that is in Phase I/II clinical trials for the treatment of tumors.

Featured Stories

Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.